News

Therma Bright’s Investment Partnership InStatin Joins Forces with InVixa to Enhance Its Patent Portfolio For The Development Of Innovative Respiratory Solutions

InStatin to secure exclusive worldwide licensing agreement of InVixa's inhaled statin solution to prevent and treat acute lung diseaseToronto, Ontario--(Newsfile…

4 weeks ago

CluePoints Appoints Richard Young as Chief Strategy Officer

KING OF PRUSSIA, Pa., Oct. 28, 2024 /PRNewswire/ -- RBQM innovator CluePoints has today announced that Richard Young has been…

1 month ago

3Aware and RQM+ Forge Partnership to Enhance MedTech Compliance and Innovation

INDIANAPOLIS, IN / ACCESSWIRE / October 28, 2024 / 3Aware, a pioneer in real-world evidence (RWE) solutions for the medical…

1 month ago

AlzeCure Presents New Positive Data for the TrkA-NAM Pain Project Against Osteoarthritis

STOCKHOLM, SE / ACCESSWIRE / October 28, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical…

1 month ago

AHIMA 2024: Showcasing Top Coding Vendors & HIM Innovations From Black Book Research Annual Industry Survey

AHIMA 2024, taking place this week in Salt Lake City, brings together industry leaders to showcase groundbreaking AI innovations reshaping…

1 month ago

ACG Presidential Plenary to Highlight Analysis of Xifaxan(R) (rifaximin) Risk Reduction of Overt Hepatic Encephalopathy (OHE) Recurrence

Additional ACG presentation to focus on impact of Xifaxan on OHE rehospitalizationsLAVAL, QC / ACCESSWIRE / October 27, 2024 /…

1 month ago

Positive Long-term Outcomes with HeartFlow FFRCT and Plaque Analysis Demonstrated in ADVANCE-DK Registry at TCT 2024

Data confirm the use of FFRCT and Plaque Analysis helps assess long-term risks, informing more personalized and effective treatment plans…

1 month ago

Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024

The detailed study results confirmed interim findings, showing stable kidney function and sustained treatment effect more than 18 months after…

1 month ago

Novartis oral Fabhalta® (iptacopan) sustained clinically meaningful results at one year in Phase III C3 glomerulopathy (C3G) trial 

New APPEAR-C3G data show Fabhalta sustained proteinuria reduction at 12 months1Upon Fabhalta initiation, improvement observed in estimated glomerular filtration rate…

1 month ago

Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024

Long-term improvements observed in the quartet of findings defining disease modification supports atacicept’s potential to prevent kidney failure in patients…

1 month ago